Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC/AML Fusion Vaccine vs Observation in AML Remission
NCT03059485Phase 2Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jun 2017
- Primary completion
- Dec 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dendritic cell-tumor fusion vaccine in acute myeloid leukemia (AML), sponsored by Beth Israel Deaconess Medical Center. Started Jun 2017; status: active, not recruiting.
02
Drugs
autologous dendritic cell-tumor fusion vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03059485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059485.